OrthO-rhumatO | VOL 12 | N°2 | 2014
18
12. Krall ea, Wehler C, garcia ri, et al. Calcium and vitamin d supplements reduce tooth loss
in the elderly. am J med 2001;111(6):452-6.
13. Krause r, Bühring m, hopfenmüller W, et al. ultraviolet B and blood pressure. lancet
1998;352(9129):709-10.
14. pfeifer m, Begerow B, minne hW, et al. effects of a short-term vitamin d(3) and calcium
supplementation on blood pressure and parathyroid hormone levels in elderly women. J
Clin endocrinol metab 2001;86(4):1633-7.
15. priemel m, von domarus C, Klatte to, et al. Bone mineralization defects and vitamin
d deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating
25-hydroxyvitamin d in 675 patients. J Bone miner res 2010;25(2):305-12.
16. luxwolda mF, Kuipers rs, Kema ip, et al. traditionally living populations in east africa
have a mean serum 25-hydroxyvitamin d concentration of 115nmol/l. Br J nutr
2012;108(9):1557-61.
17. ross aC, manson Je, abrams sa, et al. the 2011 report on dietary reference intakes for
calcium and vitamin d from the institute of medicine: what clinicians need to know. J
Clin endocrinol metab 2011;96(1):53-8.
18. holick mF, Binkley nC, Bischoff-Ferrari ha, et al. evaluation, treatment, and prevention
of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin endocrinol
metab 2011;96(7):1911-30.
19. www.health.belgium.be/internet2prd/groups/public/@public/@shc/documents/
ie2form/19066661.pdf
20. powe Ce, evans mK, Wenger J, et al. Vitamin d-binding protein and vitamin d status of
black americans and white americans. n engl J med 2013;369(21):1991-2000.
21. grbic Jt, landesberg r, lin sq, et al. incidence of osteonecrosis of the jaw in women
with postmenopausal osteoporosis in the health outcomes and reduced incidence with
zoledronic acid once yearly pivotal fracture trial. J am dent assoc 2008;139(1):32-40.
22. hansen t, Kunker m, Weber a, et al. osteonecrosis of the jaws in patients treated
with bisphosphonates histomorphologic analysis in comparison with infected
osteoradionecrosis. J oral pathol med 2006;35(3):155-60.
23. Khosla s, Burr d, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw:
report of a task force of the american society for Bone and mineral research. J Bone
miner res 2007;22(10):1479-91.
24. ruggiero s, gralow J, marx re, et al. practical guidelines for the prevention, diagnosis,
and treatment of osteonecrosis of the jaw in patients with cancer. J oncol pract
20062(1):7-14.
25. shane e, Burr d, abrahamsen B, et al. atypical subtrochanteric and diaphyseal femoral
fractures: second report of a task force of the american society for Bone and mineral
research. J Bone miner res 2014;29(1):1-23.
26. Bell JK, hayen a, irwig l, et al. the potential value of monitoring bone turnover markers
among women on alendronate. J Bone miner res 2012;27(1):195-201.
27. mcClung m. Controversies in osteoporosis management: concerns about
bisphosphonates and when are "drug holidays" required? Clin obstet gynecol
2013;56(4):743-8.
28. Baron r, Ferrari s, russell rg. denosumab and bisphosphonates: different mechanisms
of action and effects. Bone 2011;48(4):677-92.
29. Kostenuik pJ, nguyen hq, mcCabe J, et al. denosumab, a fully human monoclonal
antibody to ranKl, inhibits bone resorption and increases Bmd in knock-in mice that
express chimeric (murine/human) ranKl. J Bone miner res 2009;24(2):182-95.
30. Cummings sr, san martin J, mcClung mr, et al. denosumab for prevention of fractures in
postmenopausal women with osteoporosis. n engl J med 2009;361(8):756-65.
31. papapoulos s, lippuner K, roux C, et al. eight years of denosumab treatment in
postmenopausal women with osteoporosis. results from the first five years of the
Freedom extension. abstract lB-mo26. presented at the american society of Bone and
mineral research 2013 annual meeting; oct. 4-7, 2013; Baltimore.
32. stopeck at, lipton a, Body JJ, et al. denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast cancer: a randomized,
double-blind study. J Clin oncol 2010;28(35):5132-9.
33. Fizazi K, Carducci m, smith m, et al. denosumab versus zoledronic acid for treatment
of bone metastases in men with castration-resistant prostate cancer: a randomised,
double-blind study. lancet 2011;377(9768):813-22.
34. henry dh, Costa l, goldwasser F, et al. randomized, double-blind study of denosumab
versus zoledronic acid in the treatment of bone metastases in patients with advanced
cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin oncol
2011;29(9):1125-32.
35. stolina m, dwyer d, ominsky ms, et al. Continuous ranKl inhibition in
osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing
lymphorganogenesis or functional immune responses. J immunol 2007;179(11):7497-505.
36. Bekker pJ, holloway dl, rasmussen as, et al. a single-dose placebo-controlled study of
amg 162, a fully human monoclonal antibody to ranKl, in postmenopausal women. J
Bone miner res 2004;19(7):1059-66.
37. Watts nB, roux C, modlin JF, et al. infections in postmenopausal women with
osteoporosis treated with denosumab or placebo: coincidence or causal association?
osteoporos int 2012;23(1):327-37.
38. papapoulos s, Chaputlat r, libanati C, et al. Five years of denosumab exposure in women
with postmenopausal osteoporosis: results from the first two years of the Freedom
extension. J Bone miner res 2012;27(3):694-701.
39. lipton a, Fizazi K, stopeck at, et al. superiority of denosumab to zoledronic acid for
prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised,
phase 3 trials. eur J Cancer 2012;48(16):3082-92.
40. Body JJ, Bergmann p, Boonen s, et al. management of cancer treatment-induced bone
loss in early breast and prostate cancer a consensus paper of the Belgian Bone Club.
osteopor int 2007;18(11):1439-50.
41. gronich n, rennert g. Beyond aspirin-cancer prevention with statins, metformin and
bisphosphonates. nat rev Clin oncol 2013;10(11):625-42.
42. mhaskar r, redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a
network meta-analysis. Cochrane database syst rev 2012 may 16;5:Cd003188.
43. Ben-aharon i, Vidal l, rizel s, et al. Bisphosphonates in the adjuvant setting of breast
cancer therapy--effect on survival: a systematic review and meta-analysis. plos one
2013.8(8)e70044.
44. Valachis a, polyzos np, Coleman re, et al. ajduvant therapy with zoledronic acid
in patients with breast cancer: a systematic review and meta-analysis. oncologist
2013;18(4):353-61.
45. Wong mh, stockler mr, pavlakis n. Bisphosphonates and other bone agents for breast
cancer. Cochrane database syst rev 2012 Feb 15;2:Cd003474.
46. rennert g, pinchev m, rennert hs. use of bisphosphonates and risk of postmenopausal
breast cancer. J Clin oncol 2010;28(22):3577-81.
47. Chlebowski rt, Chen Z, Cauley Ja, et al. oral bisphosphonate use and breast cancer
incidence in postmenopausal women. J Clin oncol 2010;28(22):3582-90.
48. lopez-olivo ma, shah na, pratt g, et al. Bisphosphonates in the treatment of patients
with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
support Care Cancer 2012;20(11):2985-98.
49. rennert g, pinchev m, rennert hs, et al. use of bisphosphonates and reduced risk of
colorectal cancer. J Clin oncol 2011;29(9):1146-50.
50. pazianas m, abrahamsen B, eiken pa, et al. reduced colon cancer incidence and
mortality in postmenopausal women treated with an oral bisphosphonate--danish
national register based cohort study. osteoporos int 2012;23(11):2693-701.
51. singh h, nugent Z, demers a, et al. exposure to bisphosphonates and risk of colorectal
cancer: a population-based nested case-control study. Cancer 2012;118(5):1236-43.
52. Khalili h, huang es, ogino s, et al. a prospective study of bisphosphonate use and risk of
colorectal cancer. J Clin oncol 2012;30(26):3229-33.
53. passarelli mn, newcomb pa, laCroix aZ, et al. oral bisphosphonate use and colorectal
cancer incidence in the Women's health initiative. J Bone miner res 2013;28(9):2043-8.
54. mason md, sydes mr, glaholm J, et al. oral sodium clodronate for nonmetastatic
prostate cancer--results of a randomized double-blind placebo-controlled trial: medical
research Council pr04 (isrCtn61384873). J natl Cancer inst 2007;99(10):765-76.
55. green J, Czanner g, reeves g, et al. oral bisphosphonates and risk of cancer of
oesophagus, stomach, and colorectum: case-control analysis within a uK primary care
cohort. BmJ 2010;341 doi: http://dx.doi.org/10.1136/bmj.c4444
56. Cardwell Cr, abnet CC, Cantwell mm, et al. exposure to oral bisphosphonates and risk of
esophageal cancer. Jama 2010;304(6):657-63.
Retrouvez Ortho-Rhumato sur internet
www.ortho-rhumato.be